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Abstract. 
 
Neuroﬁlaments are transported through ax-
ons by slow axonal transport. Abnormal accumulations 
of neuroﬁlaments are seen in several neurodegenera-
tive diseases, and this suggests that neuroﬁlament trans-
port is defective. Excitotoxic mechanisms involving 
glutamate are believed to be part of the pathogenic 
process in some neurodegenerative diseases, but there 
is currently little evidence to link glutamate with neu-
roﬁlament transport. We have used a novel technique 
involving transfection of the green ﬂuorescent protein–
tagged neuroﬁlament middle chain to measure neuroﬁl-
ament transport in cultured neurons. Treatment of the 
cells with glutamate induces a slowing of neuroﬁlament 
transport. Phosphorylation of the side-arm domains of 
neuroﬁlaments has been associated with a slowing of 
neuroﬁlament transport, and we show that glutamate 
causes increased phosphorylation of these domains in 
cell bodies. We also show that glutamate activates mem-
bers of the mitogen-activated protein kinase family, and 
that these kinases will phosphorylate neuroﬁlament 
side-arm domains. These results provide a molecular 
framework to link glutamate excitotoxicity with neu-
roﬁlament accumulation seen in some neurodegenera-
tive diseases.
Key words: neuroﬁlament proteins • phosphorylation 
• amyotrophic lateral sclerosis • Alzheimer’s disease
 
Introduction
 
Neurofilaments are the major intermediate filaments of
neurons and, in mature neurons, comprise three subunit
proteins: neurofilament light chain (NF-L),
 
1
 
 neurofila-
ment middle chain (NF-M), and neurofilament heavy
chain (NF-H; for review see Lee and Cleveland, 1996).
Neurofilament proteins are synthesized in cell bodies and
transported into and through axons, with other compo-
nents of the cytoskeleton, by slow axonal transport. Neu-
rofilament and microtubule proteins travel in slow compo-
nent a, whereas actin and a number of other proteins
travel in slow component b (for reviews see Baas and
Brown, 1997; Hirokawa et al., 1997; Nixon, 1998). The
speed of transport of neurofilaments varies between 
 
z
 
0.25
and 3 mm/d, and is dependent on a number of factors, in-
cluding the type of neuron, location of neurofilament pro-
tein within the axon, and the age of the animal (Baas and
Brown, 1997; Hirokawa et al., 1997; Nixon, 1998).
Accumulations of neurofilament proteins are seen in
a number of neurodegenerative diseases. These include
amyotrophic lateral sclerosis (ALS), Parkinson’s disease,
dementia with Lewy bodies, and Alzheimer’s disease (Hi-
rano, 1991; Trojanowski et al., 1993; Schmidt et al., 1996).
Although it is not clear how neurofilament accumulations
contribute to the neurodegenerative process in these dis-
eases, their presence suggests that neurofilament transport
is somehow disrupted in affected neurons. Indeed, direct
measurements of axonal transport in several transgenic
mouse models of ALS have revealed that slowing of neu-
rofilament transport is a common and early pathological
feature (Collard et al., 1995; Zhang et al., 1997; William-
son and Cleveland, 1999).
The events that might lead to the slowing of neurofila-
ment transport are not known, but a body of evidence im-
plicates excitotoxic mechanisms involving glutamate in
several neurodegenerative diseases (Rothstein, 1996; Guo
et al., 1999). However, there is currently no direct evi-
dence to link excessive extracellular glutamate with the
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slowing of neurofilament transport. Here, we have ex-
pressed enhanced green fluorescent protein–tagged NF-M
(EGFP-NF-M) in cultured cortical neurons and show that
it is transported through neurites at rates consistent with
that of slow axonal transport. Transport of EGFP-NF-M is
via a process that requires metabolic energy. We also dem-
onstrate that treatment of the neurons with glutamate
slows the velocity of EGFP-NF-M transport.
 
Materials and Methods
 
Cell Culture
 
Intermediate filament negative SW13
 
2
 
 cells were grown in DME contain-
ing 10% (vol/vol) FBS supplemented with 2 mM glutamine, 100 IU/ml
penicillin, and 100 
 
m
 
g/ml streptomycin (GIBCO BRL). Primary cortical
neurons were obtained from E18 rat embryos and cultured on glass cover-
slips coated with poly-
 
D
 
-lysine and laminin in 12-well plates (Falcon) in
neurobasal medium and B27 supplement (GIBCO BRL) containing 100
IU/ml penicillin, 100 
 
m
 
g/ml streptomycin, and 2 mM glutamine. Cells were
cultured for 7 d and, under these conditions, were almost exclusively neu-
rons (staining with antibodies to neurofilaments and glial fibrillary acidic
protein) (Dako) revealed that glial cells comprised 
 
,
 
0.1% of the popula-
tion).
 
Plasmids and Cell Transfection
 
For expression of NF-L, NF-M, and NF-H, the rat cDNAs (Chin and
Liem, 1989, 1990) were cloned as EcoRI fragments into pCIneo (Promega).
NH
 
2
 
-terminal EGFP-tagged rat NF-M was expressed by cloning a rat
NF-M cDNA into the EcoRI site of pEGFP-C3 (CLONTECH) and
 
b
 
-galactosidase by cloning into pQBIAdCMV (Quantum) following end
repair of both insert and vector.
7-d-old primary cortical neurons were transfected by calcium phos-
phate methods using a calcium phosphate Profection kit (Promega) essen-
tially as previously described (Nikolic et al., 1996; Xia et al., 1996). In
brief, neurons grown on coverslips in 12-well plates were transfected with
6 
 
m
 
g of pEGFP-NF-M plasmid DNA prepared using an EndoFree plas-
mid kit (Qiagen). As described previously (Xia et al., 1996), the duration
of incubation with the DNA/calcium phosphate precipitate was dictated
by how fast the precipitate formed on the plate that was routinely between
10 and 20 min. The incubation was stopped 20 min later by removal of the
media and shocking with 2% DMSO/5% glycerol in Hepes-buffered sa-
line. The cells were washed three times in culture media and returned to
the incubator. The efficiency of transfection was routinely 1–3%, and
since contaminating glial cells represent 
 
,
 
0.1% of the cells in the popula-
tion, the majority of transfected cells are neurons which is in agreement
with earlier studies on cortical neurons using this transfection method (Ni-
kolic et al., 1996; Xia et al., 1996). However, some coverslips were addi-
tionally immunostained for neurofilament proteins (see below) or glial
fibrillary acidic protein to further demonstrate that transfected cells were
neurons. SW13
 
2
 
 cells were transfected as previously described using a
calcium phosphate Profection kit (Gibb et al., 1996).
 
Immunofluorescence Studies and Detection
of EGFP-NF-M
 
For immunofluorescence studies of both SW13
 
2
 
 cells and neurons, cells
were fixed in 4% (wt/vol) paraformaldehyde in PBS for 20 min, permeabi-
lized in 0.1% (wt/vol) Triton X-100 in PBS for 10 min, blocked with 5%
(vol/vol) FBS/0.2% (wt/vol) Tween 20 in PBS for 1 h, and probed with
primary antibodies diluted in blocking solution. NF-L, NF-M, and NF-H
were detected using antibodies NR4 (Sigma Chemical Co.), a polyclonal
rabbit antibody to NF-L, NN18 (Roche), SMI36, and SMI32 (Affiniti).
 
b
 
-Galactosidase was detected using a rabbit polyclonal antibody (5
 
9
 
-3
 
9
 
Inc.). Active p42 and p44 mitogen-activated protein kinases (p42/p44-
MAPKs) and active stress–activated protein kinase (SAPK) were detected
using antibodies that recognize the active forms of these kinases
(Promega). Blocking solution for the active p42/p44MAPK and SAPK an-
tibodies comprised 0.2% Tween 20 in TBS. Primary antibodies were de-
tected using goat anti–mouse or goat anti–rabbit Igs coupled to Oregon
green or Texas red (Molecular Probes), and the samples were mounted in
Vectashield (Vector labs).
For studies of transfected EGFP-NF-M in primary cortical neurons,
cells were fixed in 4% (wt/vol) paraformaldehyde in PBS, processed as
above, and mounted in Vectashield. Transfected neurons were routinely
stained with Hoechst 33258 (Molecular Probes) for analyses of nuclear
morphology and fragmentation so as to assess any potential toxicity.
Additionally, lactate dehydrogenase cell viability assays (CytoTox 96;
Promega) were utilized to determine toxicity including that induced by
glutamate. All cells were examined using a Zeiss Axioskop microscope,
and images were collected via a CCD camera (Princeton Instruments) and
analyzed using Metamorph image analysis software. Statistical analyses of
neurofilament transport rates were performed using One-way ANOVA
tests. The rate of transport was calculated using linear regression analysis.
 
L
 
-Glutamate was obtained from Sigma Chemical Co. Nifedipine (Cal-
biochem) was prepared as a 1-mM stock solution in DMSO; MK-801 and
CNQX (6-cyano-7-nitroquinoxaline-2,3-dione disodium; both from RBI)
were prepared as 1- and 5-mM stock solutions, respectively, in water. Mi-
tochondrial membrane potential was assessed by staining cells with Mi-
toTracker red (Molecular Probes) as previously described (Krohn et al.,
1999).
 
SDS-PAGE and Immunoblot Analyses
 
Primary cortical neurons were processed for SDS-PAGE by washing
twice with ice-cold PBS and scraping into ice-cold 50 mM Tris-HCl, pH
6.8, containing 5 mM EDTA, 5 mM EGTA, 6.25 
 
m
 
g/ml leupeptin, 5 
 
m
 
g/ml
aprotinin, 1.2 
 
m
 
g/ml pepstatin A, 1 mM PMSF, 50 
 
m
 
M sodium orthovana-
date, and 50 
 
m
 
M sodium fluoride. SDS-PAGE sample buffer was added,
and the samples were immediately heated in a boiling water bath. Sam-
ples were separated on 12% (wt/vol) acrylamide gels and transferred to
Protran nitrocellulose membranes (Schleicher & Schuell) using a Bio-
Rad TransBlot system. The blots were probed with antibody M12320
(Transduction Laboratories) that detects total (active and inactive) p42/
p44MAPK; anti-active p42/p44MAPK antibody (Promega); antibodies
NA1216 and NA1211 (Affiniti) that detect both phosphorylated and non-
phosphorylated NF-M and NF-H respectively; NF-L antibody NR4 and
antibody DM1A (Sigma Chemical Co.) to tubulin. After washes, the blots
were incubated with HRP-conjugated anti-mouse or anti-rabbit Igs (Am-
ersham Pharmacia Biotech), and the blots were developed using an en-
hanced chemiluminescence system (Amersham Pharmacia Biotech) ac-
cording to the manufacturer’s instructions.
 
In Vitro Phosphorylation of NF-M Side-arms by 
Mitogen-activated Protein Kinase and Stress-activated 
Protein Kinase
 
Sequences encoding the side-arm domain of rat NF-M were generated by
PCR using 
 
Pfu
 
 polymerase and primers 5
 
9
 
-CGCAGGATCCACAT-
TTTCAGGAAGCATCACTGGG-3
 
9
 
 and 5
 
9
 
-CGCAGGATCCTTAGT-
CACCCTGGGTGACTTCCTT-3
 
9
 
. These primers contain BamHI sites
that facilitated the cloning of the domain into the glutathione-S-trans-
ferase (GST) fusion vector pGEX-4T-3 (Amersham Pharmacia Biotech).
The multiphosphorylation repeat (MPR) domain of the NF-H side-arm
cloned into pGEX-3X was as described (Brownlees et al., 2000). GST,
GST-NF-M side-arm, and the GST-NF-H MPR domain were expressed in
 
Escherichia coli
 
 BL21 as described previously (Brownlees et al., 2000).
Proteins were assayed using a Bio-Rad protein assay kit according to the
manufacturer’s instructions.
NF-M side-arm and NF-H MPR domains were phosphorylated by re-
combinant MAPK or stress-activated protein kinase (SAPK/JNK3; Strat-
agene) essentially according to the manufacturer’s instructions. In brief,
equimolar amounts (34 pmol) of each substrate were incubated for 60 min
at 30
 
8
 
C with 0.185 MBq 
 
g
 
-[
 
32
 
P]ATP in 25 mM Hepes, pH 7.5, containing
10 mM magnesium acetate, 50 
 
m
 
M ATP, and either 0.02 
 
m
 
g MAPK or
0.125 
 
m
 
g SAPK in a final volume of 20 
 
m
 
l. Reactions were stopped by the
addition of SDS sample buffer, and the samples were analyzed by SDS-
PAGE and autoradiography.
 
Results
 
Transfected EGFP-NF-M Assembles into Normal 
Neurofilaments in SW13
 
2
 
 Cells and Neurons
 
We chose to study axonal transport of NF-M since NF-L
and NF-M are coordinately expressed before NF-H in ro- 
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dent neurons (Julien et al., 1986; Carden et al., 1987).
Therefore, NF-M is probably a constituent of most cellu-
lar neurofilaments. Additionally, exogenous-tagged NF-M
has been successfully used to measure neurofilament
transport in previous studies (Terada et al., 1996; Wang et
al., 2000). We tagged rat NF-M at its NH
 
2
 
 terminus with
EGFP. To demonstrate that this NH
 
2
 
-terminal addition of
EGFP does not influence NF-M assembly properties, we
studied EGFP-NF-M assembly in transfected SW13
 
2
 
 cells
that do not express intermediate filaments and in trans-
fected primary cortical neurons.
Transfection of EGFP-NF-M alone into SW13
 
2
 
 cells
resulted in the formation of NF-M–containing aggregates
but not NF-M intermediate filament networks (data not
shown). This is consistent with previous observations on
rodent neurofilament assembly properties that demon-
strate that the formation of NF-M–containing neurofila-
ments requires coexpression with NF-L (Ching and Liem,
1993; Lee et al., 1993). However, cotransfection of EGFP-
NF-M with NF-L led to filament formation (Fig. 1, a and
b) that was not noticeably different from filaments formed
by cotransfection of NF-L and untagged-NF-M (Fig. 1, c
and d). Additionally, experiments involving cotransfection
of EGFP-NF-M with NF-L and NF-H, with NF-L and
NF-M, and with NF-L, NF-M, and NF-H, all produced in-
termediate filament networks of normal appearance (all
data not shown but see Fig. 1, e and f, for networks in cells
cotransfected with EGFP-NF-M and all three untagged
neurofilament subunits).
To determine whether EGFP-NF-M was also capable of
incorporation into neurofilaments in neurons, we analyzed
neurofilament networks in EGFP-NF-M–transfected rat
cortical neurons. Here, EGFP-NF-M colocalized with NF-L
in typical neurofilament networks (Fig. 1, g and h). Thus,
NH
 
2
 
-terminal tagging of NF-M with EGFP has no notice-
able effect on its ability to coassemble into neurofilaments
in both SW13
 
2
 
 cells and neurons. These observations are
consistent with similar assembly studies of vimentin and
NF-M, which also involved NH
 
2
 
-terminal GFP-tagging of
these proteins (Ho et al., 1998; Yoon et al., 1998; Wang et
al., 2000).
 
Transfected EGFP-NF-M Is Transported through 
Neurites at Rates Consistent with that of Slow Axonal 
Transport in Cultured Neurons, and Transport 
Requires Metabolic Energy
 
To study anterograde transport of EGFP-NF-M through
neurites, we transfected rat cortical neurons with the
EGFP-NF-M plasmid, and 140 min after transfection, ana-
lyzed cells by fluorescence microscopy after fixation at 20-
min intervals for periods of up to 280 min following trans-
fection. Images of transfected cells were captured, and the
distance traveled by EGFP-NF-M at each time point was
measured. In these studies, measurements of the distance
traveled by EGFP-NF-M were taken from the cell body to
the front of the fluorescent signal and were of the longest
distances in each neuron. The fluorescent front was taken
as the most distal point at which fluorescence above back-
ground was detected. For neurites that exhibited branch-
ing, measurements were of the major neurite as deter-
mined by the length and brightness of fluorescence. To
verify the objectivity of the measurements, two indepen-
dent observers determined the distance to the fluorescent
front in the same selected transfected neurons, and the re-
sults were not significantly different. Cells were routinely
counterstained with Hoechst 33258 to assess nuclear mor-
phology and apoptosis. These studies revealed no nuclear
abnormalities or increased cell death associated with the
transfected cells, which is in agreement with previous stud-
ies of cortical neurons using this transfection method (Ni-
kolic et al., 1996).
Images of at least 20 transfected neurons for each time
point were used to calculate the average rate of transport
Figure 1. EGFP-NF-M as-
sembly in transfected SW132
cells and 7-d-old primary rat
cortical neurons. (a and b)
SW132 cells cotransfected
with EGFP-NF-M and NF-L;
a shows NF-L and b shows
EGFP-NF-M. (c and d)
SW132 cells cotransfected
with NF-L and NF-M; c
shows NF-L and d shows
NF-M. (e and f) SW132 cells
transfected with NF-L, NF-M,
NF-H, and EGFP-NF-M; e
shows NF-L and f shows
EGFP-NF-M. (g and h) Rat
cortical neurons transfected
with EGFP-NF-M; g shows
NF-L and h shows EGFP-
NF-M. Although only NF-L
and EGFP-NF-M staining are
shown in e and f, staining of
similarly transfected cells with antibodies to either NF-L and NF-M, NF-L or NF-H, and EGFP-NF-M and NF-H revealed that .90%
of cells express both plasmids. Thus, most cells appear to take up and express all three neurofilament subunits in these experiments.
Bars, 25 mm. 
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of EGFP-NF-M in each experiment (Fig. 2, representative
images of transfected cells at 140–280 min after transfec-
tion and also 24 h after transfection). Since we measured
the distance traveled by EGFP-NF-M for only up to 300
 
m
 
m from the cell body, and since the average length of the
major neurites in the transfected cortical neurons ex-
ceeded 700 
 
m
 
m, the assays are of transport within neurites
and are not a reflection of EGFP-NF-M in neurite termi-
nals and neurite growth rates. The average length of neu-
rites in the cultures and also their rate of growth was de-
termined by transfection of 
 
b
 
-galactosidase and staining
for this enzyme 24 h later. 
 
b
 
-Galactosidase has been used
on many occasions to determine the shape of neurons, and
is known to be present in growth cones (Nikolic et al.,
1996). These studies demonstrated that the average length
of neurites 24 and 28 h after transfection was 777.5
 
 6 
 
25.1
 
m
 
m and 780.3
 
 6 
 
21.8 
 
m
 
m, respectively (not significantly
different using One-way ANOVA test;
 
 P 
 
5 
 
0.932).
From these analyses, we calculated that the average rate
of transport of EGFP-NF-M was 80 
 
6 
 
2 
 
m
 
m/h (Fig. 3). Al-
though this rate of transport of EGFP-NF-M showed no
noticeable differences between experiments (compare, for
example, the rate of transport of EGFP-NF-M in Figs. 3
and 4, which are from two different experiments), the av-
erage distance traveled at the first time point (140 min)
differed by 
 
z
 
15 
 
m
 
m between experiments. We attribute
this to differences between transfections for each experi-
ment that result in small variations in the precise time at
which EGFP-NF-M is first expressed. Indeed, the period
of incubation with the DNA/calcium phosphate precipi-
tate during transfection varies by 
 
z
 
10 min depending on
the time in which a particular precipitate takes to form on
the cells (see Materials and Methods). This 10-min varia-
tion is in keeping with the differences observed between
experiments in the average distance traveled by EGFP-
NF-M at each time point. Other groups have also reported
that the time taken for DNA/calcium phosphate precipi-
tates to form on neurons using this transfection method is
variable and can lead to small differences in the incubation
period (Xia et al., 1996). However, to facilitate compari-
sons between different experiments, we have adjusted the
displayed figures (Figs. 3 and 4) so that the distance trav-
eled by EGFP-NF-M is calculated as the distance from the
first measurement (i.e., 140 min after transfection); the
distance traveled at this first data point is, therefore, re-
corded as zero.
To determine whether transport of EGFP-NF-M re-
quires metabolic energy, measurements were taken from
cells treated for 30 min with 50 mM 2-deoxy-
 
D
 
-glucose/
Figure 2. Transport of EGFP-NF-M in transfected cortical neu-
rons. Representative images of EGFP-NF-M–transfected cortical
neurons at (a) 140, (b) 160, (c) 180, (d) 200, (e) 220, (f) 240, (g)
260, and (h) 280 min, and (i) 24 h after transfection are shown. (j)
Also shown is an EGFP-transfected neuron 240 min after trans-
fection. Bars, 100 mm.
Figure 3. Analyses of EGFP-NF-M transport in transfected neu-
rons. Points shown are distances traveled by EGFP-NF-M at
140–280 min after transfection. For 2-deoxy-D-glucose/sodium
azide treatment, cells were treated for the first 30 min. The data
sets shown are from one representative experiment and error
bars are SEM. One-way ANOVA tests showed significant differ-
ences between untreated and 2-deoxy-D-glucose/sodium azide–
treated neurons at the 160-min time point (P 5 0.026) and at all
later time points (P , 0.001). 
Ackerley et al. 
 
Glutamate Slows Transport of Neurofilaments
 
169
 
0.05% sodium azide, 140 min after transfection. This treat-
ment is known to halt energy-dependent processes includ-
ing motile properties of transfected vimentin in living cells
(Yoon et al., 1998); 2-deoxy-
 
D
 
-glucose inhibits glycolysis
at an early step, whereas sodium azide inhibits electron
transport at the last step. 2-Deoxy-
 
D
 
-glucose/sodium azide
retarded transport but, after washout and a recovery pe-
riod, EGFP-NF-M movement resumed at a rate that was
not noticeably different from that of untreated cells (Fig.
3). The absence of a complete arrest to EGFP-NF-M
movement at the 160-min time point may be because up-
take of 2-deoxy-
 
D
 
-glucose/0.05% sodium azide and inhibi-
tion of metabolic processes takes some minutes. These
observations are similar to those seen in GFP-vimen-
tin–transfected fibroblasts, where 2-deoxy-
 
D
 
-glucose/
sodium azide also halts motility but, after washout and a
similar recovery period, vimentin movements resume (Yoon
et al., 1998).
For comparison, we also studied anterograde movement
of transfected EGFP in cortical neurons since there is no
evidence to suggest that EGFP is transported by slow ax-
onal transport and it might, therefore, move at a different
rate. In contrast to EGFP-NF-M, EGFP was detected
along the length of neurites at the time point assayed (240
min after transfection; Fig. 2 j). This indicates that a pro-
portion of EGFP may move by fast transport mechanisms
since this rate of movement is probably incompatible with
simple diffusion (Sabry et al., 1995). This observation also
suggests that, in the EGFP-NF-M transfections, EGFP re-
mains covalently attached to NF-M and has not been re-
leased by a proteolytic event. Thus, transfected EGFP-
NF-M is transported through neurites of cultured primary
 
cortical neurons at 
 
z
 
80 
 
m
 
m/h, a rate different to that of
EGFP and consistent with the known rates of slow axonal
transport, and this movement requires metabolic energy.
 
Glutamate Inhibits Transport of
Transfected EGFP-NF-M
 
To study how the treatment of neurons with glutamate in-
fluenced EGFP-NF-M transport rates, we treated cells
with 500, 50, and 30 
 
m
 
M glutamate. Glutamate treatment
was applied 140 min after transfection (i.e., at the same
time as the first recording of distance traveled was made)
and maintained over the course of the experiment. 7-d-old
cortical neurons are known to be susceptible to glutamate
treatment and to express glutamate receptors (Cheng et
al., 1994; Davis et al., 1995). Although glutamate had no
significant effect on EGFP-NF-M movement over the
first 20 min, at later time points, a significant inhibition of
transport was observed. The extent of this inhibition of
EGFP-NF-M transport was related to the concentration
of glutamate applied to the cultures (Fig. 4).
Previous studies have shown that treatment of cultured
cortical neurons with concentrations of up to 1 mM glu-
tamate, for periods in excess of the times used here, does
not influence cell viability (Davis et al., 1995). Indeed, the
Hoechst 33258 staining that we routinely performed to
monitor viability of the cells revealed no evidence of in-
creased cell death over the period of treatment. However,
to confirm that the slowing of EGFP-NF-M transport was
not due to a simple loss of viability of the cells, we per-
formed lactate dehydrogenase cell viability assays on
glutamate-treated cells for periods of up to 180 min (i.e.,
longer than the 120-min period in which EGFP-NF-M
transport was studied in the presence of glutamate). These
studies revealed that there was no significant loss of viabil-
ity over the time course of the experiment (data not
shown), which is in agreement with previous reports of
glutamate-treated cortical neurons (Davis et al., 1995).
To further confirm that this slowing of EGFP-NF-M
transport was induced by the glutamate treatment, and to
determine which glutamate receptor subtype(s) might me-
diate this effect, we studied EGFP-NF-M transport in ei-
ther untreated or 50 
 
m
 
M glutamate-treated neurons, in the
presence or absence of ionic glutamate receptor antago-
nists. Treatment with 5 
 
m
 
M CNQX (AMPA/kainate receptor
blocker) had no significant effect on glutamate-induced re-
tardation of the distance traveled; however, 1 
 
m
 
M MK-801
(NMDA receptor blocker) completely inhibited the effect
of glutamate (Fig. 5). We also treated cells with 1 
 
m
 
M nifed-
ipine, an inhibitor of L-type voltage-gated calcium chan-
nels, which are activated after depolarization of the post-
synaptic membrane (Ghosh and Greenberg, 1995). However,
nifedipine had no effect on glutamate-induced slowing of
EGFP-NF-M transport (Fig. 5).
We also studied whether glutamate induced changes in
the levels of NF-L, NF-M, and NF-H or tubulin proteins in
the neurons by immunoblotting (Fig. 6). However, no al-
terations to the steady state levels of any of these proteins
were detected. Finally, we assessed the mitochondrial
membrane potential after glutamate treatment by staining
with the probe MitoTracker red. These studies did not
reveal any changes to mitochondria in response to gluta-
Figure 4. Glutamate inhibits EGFP-NF-M transport in trans-
fected neurons. Points shown are distances traveled by EGFP-
NF-M at 140–260 min after transfection. Cells were untreated or
treated with 500, 50, or 30 mM glutamate. Glutamate was applied
at the 140-min time point. The data sets shown are from one rep-
resentative experiment and error bars are SEM. One-way
ANOVA tests revealed no significant differences between un-
treated and glutamate-treated neurons at the 160-min time point
(untreated versus 30 mM glutamate, P 5 0.285; untreated versus
50 mM glutamate, P 5 0.701; untreated versus 500 mM glutamate,
P 5 0.447). Significant differences between untreated and both
500 mM glutamate (P , 0.001) and 50 mM glutamate (P , 0.001),
but not 30 mM glutamate (P 5 0.132), treatments were detected
at the 180-min time point. At later time points, significant differ-
ences were detected between untreated and all glutamate treat-
ments (P , 0.001). 
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mate over the time periods used for investigating EGFP-
NF-M transport (data not shown). Thus, over the time
course studied, glutamate retards anterograde transport of
EGFP-NF-M in cultured cortical neurons without affect-
ing cell viability or neurofilament protein levels, and this
effect is mediated at least, in part, through NMDA-type
glutamate receptors.
 
Glutamate Activates Members of the MAP Kinase 
Family and Induces Increased Phosphorylation of
NF-M/NF-H Side-arms, and NF-M/NF-H Side-arms 
Are Substrates for MAP Kinases
 
Many studies have shown that increased phosphorylation
of NF-M and NF-H side-arms is associated with a slowing
of neurofilament transport (Watson et al., 1989a,b, 1991;
Archer et al., 1994; Nixon et al., 1994a,b; Jung and Shea,
1999). Since glutamate is known to activate a number of
kinases in neurons (see below), the slowing in the rate of
EGFP-NF-M transport observed in response to glutamate
may be due (at least in part) to increased phosphorylation
of neurofilament side-arms. Much of the phosphate that is
incorporated into NF-M/NF-H side-arms is on serines
within the motif Lys-Ser-Pro, and this suggests that the
responsible kinases are proline-directed kinases. Proline-
directed kinases that have been shown to phosphorylate
NF-M/NF-H side-arms include cyclin-dependent kinase-5
(cdk5), glycogen synthase kinase-3, and members of the
MAPK family including p42/p44MAPK and SAPK1b/c
(Guan et al., 1991; Lew et al., 1992; Hisanaga et al., 1993;
Miyasaka et al., 1993; Shetty et al., 1993; Giasson and
Mushynski, 1996, 1997; Guidato et al., 1996; Sun et al., 1996;
Bajaj and Miller, 1997; Li et al., 1999; Veeranna et al.,
1998; Brownlees et al., 2000). 
We have recently demonstrated that, in rat cortical neu-
rons (as used here), glutamate activates SAPK1b but has
no effect on cdk5 activity and causes a decrease in glyco-
gen synthase kinase-3 activity (Brownlees et al., 2000).
Others have also shown that glutamate activates SAPKs in
neurons (Bading and Greenberg, 1991; Kurino et al., 1995;
Xia et al., 1996; Kawasaki et al., 1997; Schwarzschild et al.,
1997, 1999). However, we did not investigate the effect
that glutamate has on p42/p44MAPK activities in our ear-
lier studies, and rectified this omission by the use of anti-
bodies that detect total and active p42/p44MAPK. These
studies demonstrated that glutamate induced a marked ac-
tivation of both MAPK isoforms, and that this activation
extended for at least 120 min (i.e., the time course over
which EGFP-NF-M transport was studied; Fig. 6). Others
have also shown that glutamate can activate p42/p44-
MAPK in neurons (Bading and Greenberg, 1991; Kurino
et al., 1995; Xia et al., 1996; Schwarzschild et al., 1999).
Thus, p42/p44MAPK and SAPKs are good candidates for
altering NF-M/NF-H side-arm domain phosphorylation in
response to glutamate.
We also studied the subcellular localization of active
p42/p44MAPK and SAPKs in the neurons using antibod-
ies that detect the active forms of these kinases. In un-
treated cells, active p42/p44MAPK was only weakly de-
tected where it localized to cell bodies and some neurites
(Fig. 7 a); active SAPK was present mainly in neurites
(Fig. 7 c). Treatment with glutamate induced a marked in-
crease in active p42/p44MAPK labeling in both cell bodies
(including some nuclei) and neurites (Fig. 7 b). Similarly,
glutamate also increased labeling for active SAPKs, partic-
ularly in cell bodies and nuclei (Fig. 7 d).
NF-M side-arms are phosphorylated by p42/p44MAPK
(Veeranna et al., 1998; Li et al., 1999) and SAPK1b, which
is a major SAPK in neurons (Mohit et al., 1995; Martin et
al., 1996; Carboni et al., 1997, 1998; Lee et al., 1999), has
been shown to phosphorylate NF-H side-arms (Brownlees
et al., 2000). However, there is currently little data to dem-
onstrate that SAPK1b will phosphorylate NF-M side-arms.
Therefore, we prepared the side-arm domain of NF-M as a
GST fusion protein and tested its ability to be phosphory-
Figure 5. Effect of glutamate receptor antagonists on glutamate-
induced inhibition of EGFP-NF-M transport. Histogram shows
distance traveled by EGFP-NF-M 240 min after transfection in
either untreated or 50-mM glutamate-treated neurons in the pres-
ence or absence of 1 mM MK-801, 5 mM CNQX, or 1 mM nifed-
ipine. Glutamate was applied at the 140-min time point and in-
hibitors 10 min before this. Data from one representative
experiment are shown. Asterisks indicate treatments that dis-
play significant differences (P , 0.001) compared with 50-mM
glutamate treatment as analyzed by One-way ANOVA tests. No
significant difference was observed between untreated neurons
and neurons treated with glutamate in the presence of MK801.
Error bars are SEM.
Figure 6. Glutamate activates
p42 and p44 MAPKs and does
not alter the levels of neurofila-
ment or tubulin proteins in corti-
cal neurons. 7-d-old cortical neu-
rons were either untreated (un),
or treated with 100 mM glu-
tamate for 30, 60, or 120 min,
and then analyzed by 12% SDS-
PAGE and immunoblotting. No
change in the total levels of ei-
ther p42 or p44 MAPK (arrow-
heads), but a noticeable increase
in the active forms of both these
kinases was observed after
glutamate treatment. Glutamate
did not alter the levels of NF-L,
NF-M, NF-H, or tubulin. An
identically loaded Coomassie-stained gel is shown at the bottom
to demonstrate equal protein loading of the samples.Ackerley et al. Glutamate Slows Transport of Neurofilaments 171
lated by recombinant SAPK1b. For comparisons, we also
used as a substrate the MPR domain of NF-H side-arms
that contains the Lys-Ser-Pro repeat region (Brownlees et
al., 2000) and recombinant p42MAPK. Both NF-M and
NF-H substrates, but not GST, were phosphorylated by
p42MAPK and SAPK1b (Fig. 8). Not all Ser-Thr-Pro mo-
tifs are phosphorylated under these conditions, since we
have shown that Thr668 in the Alzheimer’s disease amy-
loid precursor protein, which is a known in vivo phos-
phorylation site, is not phosphorylated by MAPK (Aplin
et al., 1996).
We next examined if glutamate induced alterations to
the phosphorylation of NF-M/H side-arms in vivo in corti-
cal neurons. SMI36, an antibody that reacts with phosphor-
ylated but not nonphosphorylated NF-M/NF-H side-arms
(Sternberger and Sternberger, 1983), labeled neurites but
only weakly labeled cell bodies in untreated cells (Fig. 7
e). This is consistent with many studies, which have shown
that NF-M and NF-H side-arms are heavily phosphory-
lated in axons but are much less phosphorylated in cell
bodies and proximal axons (Julien and Mushynski, 1982;
Sternberger and Sternberger, 1983; Carden et al., 1985;
Lee et al., 1987, 1988; Nixon et al., 1994b). However,
glutamate induced a marked increase in SMI36 labeling
of cell bodies that was evident as early as 30 min after
glutamate treatment (Fig. 7 f). We also confirmed that
glutamate induced an increased cell body phosphorylation
of NF-M/NF-H side-arms in the EGFP-NF-M–transfected
neurons by the staining of transfected cultures with SMI36
(Fig. 9, a–d). Thus, glutamate activates members of the
MAP kinase family including p42/p44MAPK and SAPK1b,
neurofilament side-arm domains are substrates for these
kinases, and glutamate induces increased phosphorylation
of neurofilament side-arms in cell bodies of cortical neu-
rons.
Finally, we analyzed whether the glutamate-induced
slowing of EGFP-NF-M transport might lead to the for-
mation of neurofilament accumulations such as are seen in
some neurodegenerative diseases. Accumulations typical
of these disorders were rarely detected over the time
course in which transport rates were studied (140–260 min
after transfection and 120-min glutamate treatment). How-
ever, after 180 min of glutamate treatment (i.e., 320 min
after transfection), increased EGFP-NF-M labeling and
swelling of proximal neurites become more noticeable in a
proportion of the neurons. To quantify this more carefully,
we randomly captured images of EGFP-NF-M–trans-
fected cells either untreated or treated with 100 mM
glutamate at this time point and scored them blind for the
presence of accumulations. In two different experiments,
accumulations typical of the ones shown in Fig. 10 (see
also accumulation in Fig. 9 double labeled with SMI36)
were found in greater numbers in the glutamate-treated
cells (experiment 1, 29.6% treated [n 5 81] versus 7.6%
untreated [n 5 92]; experiment 2, 33.3% treated [n 5 69]
versus 9.9% [n 5 111]). The accumulations seen in un-
treated neurons may be a consequence of increased ex-
Figure 7. Localization of active p42/p44MAPK, SAPKs, and
phosphorylated NF-M/NF-H side-arms (SMI36 labeling) in un-
treated and glutamate-treated 7-d-old cortical neurons. a, c, and e
are untreated cells; b, d, and f are treated with 100 mM glutamate
for 30 min. Increased labeling for active p42/p44MAPK (a and b)
and SAPKs (c and d) is seen after glutamate treatment. SMI36 la-
beling is markedly increased in cell bodies after glutamate expo-
sure (e and f). Bar, 25 mm.
Figure 8. In vitro phosphorylation of NF-M side-arm and the
MPR domain of NF-H side-arm with p42MAPK and SAPK1b.
Left panels are phosphorylation by p42MAPK, and right panels
are phosphorylation using SAPK1b. The top panels are the auto-
radiographs, and the bottom panels are the corresponding Coo-
massie-stained gels. RM are reaction mixes only without GST/
NF-M/NF-H substrates; GST are reaction mixes with GST sub-
strate; NF-M are reaction mixes with NF-M substrate; and NF-H
are reaction mixes with the NF-H MPR domain substrate. Minus
and plus signs refer to the absence or inclusion of kinases in the
reaction mixes. The lower molecular mass species seen in tracks
containing the NF-M side-arm domain are probably proteolytic
degradation products since many of these react with NF-M anti-
bodies. We were unable to inhibit this proteolysis despite using
cocktails of protease inhibitors.The Journal of Cell Biology, Volume 150, 2000 172
pression of EGFP-NF-M since overexpression of NF-M in
transgenic mice can also lead to neurofilament accumula-
tions (Vickers et al., 1994; Wong et al., 1995).
Discussion
Anterograde axonal transport of the cytoskeleton has
been studied using a variety of experimental systems both
in vivo and in cultured cells (for reviews see Baas and
Brown, 1997; Hirokawa et al., 1997; Nixon, 1998). These
include monitoring the movement of radiolabeled proteins
(Reinsch et al., 1991; de Waegh et al., 1992; Lasek et al.,
1992; Archer et al., 1994; Nixon et al., 1994b; Collard et al.,
1995; Campenot et al., 1996; Zhang et al., 1997; William-
son and Cleveland, 1999), the use of fluorescently labeled
cytoskeletal proteins, and photoactivation and photo-
bleaching techniques (Keith, 1987; Okabe and Hirokawa,
1992, 1993; Okabe et al., 1993; Takeda et al., 1994, 1995;
Sabry et al., 1995; Funakoshi et al., 1996; Miller and Joshi,
1996; Yu et al., 1996), analyses of cytoskeletal accumula-
tion after physical constriction of axons (Koehnle and
Brown, 1999), and, finally, studies of labeled cytoskeletal
proteins introduced into neurons using recombinant DNA
methodologies (Terada et al., 1996; Yabe et al., 1999;
Wang et al., 2000). The new method that we describe here
complements these existing techniques and offers certain
advantages. First, it can be applied to any cytoskeletal pro-
tein whose properties are not influenced by tagging with
EGFP. Second, since it involves transfection of cytoskele-
tal cDNAs, analyses of mutants and the effect of overex-
pression of other proteins that might influence transport
by cotransfection methods are possible. Third, the effects
that various physiological agents have on slow axonal
transport are easily studied (such as we have described
here with glutamate and glutamate receptor antagonists).
Finally, the method is not technically demanding and is
simple to perform; the fluorescent front is discrete and
easily observed and the error bars for distance traveled by
EGFP-NF-M are small and this testifies to the quality of
the data. Thus, our method is simple and robust.
In vivo, neurofilament transport rates vary between
z10–125 mm/h depending on the type of neuron, age of
the animal, and location within the axon (Lee and Cleve-
land, 1996; Baas and Brown, 1997; Hirokawa et al., 1997;
Nixon, 1998). However, recent cellular studies have shown
that neurofilaments travel at fast transport rates (up to 2.3
mm/s), but that this movement is interrupted by prolonged
pauses (Wang et al., 2000). Therefore, only a proportion of
neurofilaments are moving at any one time (estimated as
1–15%), such that an overall slow transport rate is ob-
served. Since we analyzed EGFP-NF-M movement in cells
fixed at 20-min intervals rather than in living cells, our as-
says calculate this overall slow transport rate. In the corti-
cal cells used, this is 80 6 2 mm/h, which is consistent with
the known rates of transport as assayed in vivo by other
methods.
Abnormal accumulations of neurofilament proteins are
seen in ALS, Alzheimer’s disease, and Lewy bodies in Par-
kinson’s disease and Lewy body dementia (Hirano, 1991;
Trojanowski et al., 1993; Schmidt et al., 1996). Such accu-
mulations suggest that the transport of neurofilament pro-
teins through axons is disrupted in these disease states.
Indeed, measurements of axonal transport in several
transgenic mouse models of ALS reveal that the slowing
of cytoskeletal transport is an early pathological feature
(Collard et al., 1995; Zhang et al., 1997; Williamson and
Cleveland, 1999).
The events that lead to cell death in these neurodegen-
erative diseases are not known, but excitotoxic mecha-
nisms involving glutamate have been suggested to be part
of the disease process for both ALS (for reviews see Shaw,
1994; Rothstein, 1996) and Alzheimer’s disease (Guo et
al., 1999). Indeed, a loss of the glial glutamate transporter
(EAAT2) has been described in sporadic forms of ALS
(Lin et al., 1998) and in a transgenic mouse model of ALS
(Bruijn et al., 1997). Moreover, mutant SOD1s, which
cause familial forms of ALS, induce selective damage to
EAAT2 by oxidative mechanisms (Trotti et al., 1999); up-
take of glutamate via sodium-dependent glutamate trans-
porters is a primary mechanism for inactivation of extra-
cellular glutamate. Thus, glutamate-induced excitotoxicity
might be part of the pathogenic process in several neuro-
Figure 9. Glutamate induces increased phosphorylation of NF-
M/NF-H side-arms in cell bodies of EGFP-NF-M–transfected
neurons. Cells were transfected with EGFP-NF-M and, 320 min
after transfection, were fixed and immunostained with SMI36. a
and b are untreated; c and d are treated with 100 mM glutamate
for 180 min. a and c show EGFP-NF-M; b and d show SMI36 la-
beling. Note the proximal accumulation of neurofilament protein
in the glutamate-treated cell. Bar, 25 mm.
Figure 10. EGFP-NF-M accumulations begin to develop in prox-
imal neurites of some transfected neurons treated with 100 mM
glutamate for 180 min (i.e., 320 min after transfection). Images
shown are of EGFP-NF-M in proximal regions of neurites 320
min after transfection in untreated cells (a–c) and cells treated
with 100 mM glutamate for 180 min and in which neurofilament
accumulations are starting to develop (d–f). Bar, 25 mm.Ackerley et al. Glutamate Slows Transport of Neurofilaments 173
degenerative diseases. Our finding that glutamate inhibits
anterograde axonal transport of NF-M, therefore, pro-
vides a mechanism to link excitotoxicity with neurofila-
ment accumulation in these disorders.
The series of molecular events by which glutamate ex-
posure might lead to a slowing of neurofilament transport
are not clear. However, increased phosphorylation of NF-M
and NF-H side-arm domains has been associated with
slower neurofilament transport rates in many studies
(Watson et al., 1989a,b, 1991; Archer et al., 1994; Nixon et
al., 1994a,b; Jung and Shea, 1999). Therefore, it is notable
that we observe an increase in neurofilament side-arm
phosphorylation in cell bodies after glutamate treatment.
Other studies have shown that glutamate can cause in-
creased neurofilament side-arm phosphorylation in neu-
rons (Asahara et al., 1999; Brownlees et al., 2000). NF-M
and NF-H side-arms are more heavily phosphorylated in
axons than cell bodies (Julien and Mushynski, 1982; Stern-
berger and Sternberger, 1983; Carden et al., 1985; Lee et
al., 1987, 1988; Nixon et al., 1994b), and so it is also possi-
ble that changes to neurofilament phosphorylation oc-
curred in neurites but were not so easily detectable.
Glutamate is known to activate members of the MAPK
family including p42/p44MAPK and SAPKs (Bading and
Greenberg, 1991; Kurino et al., 1995; Xia et al., 1996;
Schwarzschild et al., 1997, 1999; Brownlees et al., 2000),
and we demonstrate that this is also the case in the cortical
neurons used here. p42/p44MAPK and SAPK1b/c will all
phosphorylate NF-M/NF-H side-arms (Giasson and Mushyn-
ski, 1996, 1997; Veeranna et al., 1998; Li et al., 1999;
Brownlees et al., 2000; data shown here), and we show that
the active forms of these kinases are present in cell bodies
in the glutamate-treated neurons. Together, these obser-
vations suggest that these particular kinases are the link
between glutamate and increased neurofilament phos-
phorylation.
Thus, activation of p42/p44MAPK and SAPKs, and
phosphorylation of NF-M/NF-H side-arms might be at
least part of the process by which glutamate causes a slow-
ing of neurofilament transport in the cortical neurons used
here. Whether the same processes occur in other neuronal
cell types including lower motor neurons remains to be es-
tablished. However, other possible mechanisms including
glutamate-induced alterations to the neurofilament trans-
port motor, which has to date not been identified, or the
way in which neurofilaments attach to the motor, which is
again not known (Brady, 2000), cannot be excluded. In-
deed, one recent suggestion is that NF-M/NF-H side-arm
phosphorylation regulates association of neurofilaments
with kinesin, a fast motor (Yabe et al., 2000). Whatever
the precise mechanism, the results presented here are the
first to show a link between glutamate excitotoxicity, a
proposed pathogenic process for several human neurode-
generative diseases, and slowing of neurofilament trans-
port, which is a pathological feature in at least some of
these disorders.
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